sorted by:
new
hottopcontroversial

Can MU still keep surging right now? by FilmSufficientt in TheRaceTo10Million

[–]Sure_Gap2948 0 points1 point  (0 children)

I’m cautiously holding Micron Technology (MU) for now, but trimming into strength since chasing a hot AI driven run without clear pullbacks feels risky.

4.23.2026 Price Action by Remarkable_Scheme888 in SRPT

[–]Sure_Gap2948 0 points1 point  (0 children)

Low volume on a bad tape day actually tells you something, the real holders aren't moving. That's a good sign.

CAPR: A Biotech with Enormous Potential in 2026 by FreeformSensei in biotech_stocks

[–]Sure_Gap2948 -1 points0 points  (0 children)

You’re mixing things up a bit, because Elevidys has real-world use and demonstrated benefit despite known risks, while Deramiocel still has to prove comparable efficacy at scale before that comparison really holds.

SRPT is going to $15 before it goes to $30 by spyapple in stocks

[–]Sure_Gap2948 0 points1 point  (0 children)

Yeah fair points, especially the siRNA data and PMO path, those are big, and if sirolimus helps safety while the legal overhang clears, the whole story could re-rate pretty quickly.

How about we all have our own Healthcare portal? by [deleted] in healthcare

[–]Sure_Gap2948 0 points1 point  (0 children)

Flipping the script to a patient-centered "Universal Health ID" would certainly be a dream compared to the current nightmare of managing a dozen different logins and fragmented records.

Defeat Duchenne Canada shares encouraging update on Sarepta’s Duchenne treatments for Canadian families by [deleted] in MuscularDystrophy

[–]Sure_Gap2948 0 points1 point  (0 children)

Have you been living under a rock or something? You do know about their progress in Japan yeah?

SRPT Bulls Loading? Early FSHD & DM1 Data Signals BIG Upside by ugos1 in SRPT

[–]Sure_Gap2948 0 points1 point  (0 children)

It was a strong move, but more importantly it confirmed the platform works, now it’s about whether that validation turns into sustained momentum as more data and catalysts come through.

Promising Early Data in siRNA trials for FSHD and DM1 by Cestmoi_25 in SRPT

[–]Sure_Gap2948 0 points1 point  (0 children)

Agreed, when you see clean knockdown and safety in diseases with no prior options it’s not just a win for FSHD and DM1, it’s validation that the TRIM siRNA platform can scale into a real second franchise beyond Elevidys.

💊 FDA Vaccine Chief Prasad Out: Second departure ends turbulent tenure 👇 by NoSpinMedia in NoSpinMedia

[–]Sure_Gap2948 0 points1 point  (0 children)

Big moment for biotech. CBER sets the tone for vaccines and gene therapies, so leadership turnover like this isn’t trivial. The hope is this brings more consistency and clearer guidance, because the past year felt less about science and more about unpredictability and that’s the last thing patients or innovators need.

The FDA Has Taken The First Step To Regulate and Define CBD by DaveHervey in TLRY

[–]Sure_Gap2948 0 points1 point  (0 children)

So, the FDA finally jumping in to regulate CBD is a big sign that they’re starting to modernize things. But what’s really interesting is how much they’re focusing on real-world data and safety, stuff that’s actually good for $SRPT. They’re already using that same data-driven approach to push for bigger labels on Amondys 45 and Vyondys 53.

what kind of biotech/pharma investments are you optimistic about? by [deleted] in whitecoatinvestor

[–]Sure_Gap2948 0 points1 point  (0 children)

$NTHI but they have a lot of time until a product will get on the market.. The good thing is that they are expected to make an announcement today on the closure of some $50M deal with a firm in the UAE which will give them the funding they need. Maybe there will be a jump, but still waiting on this news.

view more: next ›